ES2620264T3 - Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer - Google Patents

Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer Download PDF

Info

Publication number
ES2620264T3
ES2620264T3 ES11847198T ES11847198T ES2620264T3 ES 2620264 T3 ES2620264 T3 ES 2620264T3 ES 11847198 T ES11847198 T ES 11847198T ES 11847198 T ES11847198 T ES 11847198T ES 2620264 T3 ES2620264 T3 ES 2620264T3
Authority
ES
Spain
Prior art keywords
antibodies against
humanized antibodies
treat cancer
liv
against liv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11847198T
Other languages
English (en)
Spanish (es)
Inventor
Maria Leia Smith
Django Sussman
William Arthur
Albina Nesterova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Application granted granted Critical
Publication of ES2620264T3 publication Critical patent/ES2620264T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES11847198T 2010-12-06 2011-12-06 Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer Active ES2620264T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42029110P 2010-12-06 2010-12-06
US201161446990P 2011-02-25 2011-02-25
PCT/US2011/063612 WO2012078688A2 (en) 2010-12-06 2011-12-06 Humanized antibodies to liv-1 and use of same to treat cancer

Publications (1)

Publication Number Publication Date
ES2620264T3 true ES2620264T3 (es) 2017-06-28

Family

ID=46207694

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11847198T Active ES2620264T3 (es) 2010-12-06 2011-12-06 Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer
ES18204152T Active ES2842895T3 (es) 2010-12-06 2011-12-06 Anticuerpos humanizados contra LIV-1 y uso de los mismos para tratar el cáncer
ES16200557T Active ES2719548T3 (es) 2010-12-06 2011-12-06 Anticuerpos humanizados para liv-1 y uso de los mismos para tratar el cáncer

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES18204152T Active ES2842895T3 (es) 2010-12-06 2011-12-06 Anticuerpos humanizados contra LIV-1 y uso de los mismos para tratar el cáncer
ES16200557T Active ES2719548T3 (es) 2010-12-06 2011-12-06 Anticuerpos humanizados para liv-1 y uso de los mismos para tratar el cáncer

Country Status (25)

Country Link
US (6) US9228026B2 (OSRAM)
EP (4) EP3156420B1 (OSRAM)
JP (6) JP6105481B2 (OSRAM)
KR (5) KR20220011811A (OSRAM)
CN (1) CN103533957B (OSRAM)
AU (4) AU2011338480B8 (OSRAM)
BR (2) BR122021020513B1 (OSRAM)
CA (2) CA3211246A1 (OSRAM)
CY (3) CY1118874T1 (OSRAM)
DK (3) DK3156420T3 (OSRAM)
ES (3) ES2620264T3 (OSRAM)
HR (1) HRP20170567T1 (OSRAM)
HU (3) HUE052806T2 (OSRAM)
IL (4) IL299837A (OSRAM)
LT (1) LT2648752T (OSRAM)
MX (3) MX379481B (OSRAM)
NZ (1) NZ611468A (OSRAM)
PL (3) PL3156420T3 (OSRAM)
PT (3) PT3156420T (OSRAM)
RS (1) RS55843B1 (OSRAM)
RU (1) RU2608646C2 (OSRAM)
SG (3) SG10201510041QA (OSRAM)
SI (3) SI2648752T1 (OSRAM)
WO (1) WO2012078688A2 (OSRAM)
ZA (1) ZA201303803B (OSRAM)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3211246A1 (en) 2010-12-06 2012-06-14 Seagen Inc. Humanized antibodies to liv-1 and use of same to treat cancer
CN110818798A (zh) 2012-10-25 2020-02-21 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
RS63212B1 (sr) 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
ES2871816T3 (es) 2012-12-27 2021-11-02 Sanofi Sa Anticuerpos anti-LAMP1 y conjugados anticuerpo-fármaco, y usos de los mismos
US20160193295A1 (en) * 2013-07-31 2016-07-07 Amgen Inc. Stabilization of fc-containing polypeptides
AU2014337555C1 (en) 2013-10-15 2021-01-28 Seagen Inc. PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
MX385823B (es) 2014-02-17 2025-03-18 Seagen Inc Conjugados de anticuerpo-farmaco hidrofilicos.
HUE061076T2 (hu) 2015-04-06 2023-05-28 Bioverativ Usa Inc Humanizált anti-C1s ellenanyagok alkalmazási eljárások
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
HK1259075A1 (zh) 2016-02-17 2019-11-22 Seattle Genetics, Inc. Bcma抗体和其用以治疗癌症和免疫病症的用途
MA45324A (fr) * 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
KR102626498B1 (ko) 2016-03-25 2024-01-19 씨젠 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
EP3496747A4 (en) 2016-08-09 2020-04-15 Seattle Genetics, Inc. Drug conjugates with self-stabilizing linkers having improved physiochemical properties
EA201891851A1 (ru) * 2016-09-16 2019-04-30 Сиэтл Дженетикс, Инк. Антитела против bcma и их применение для лечения злокачественных новообразований и иммунологических нарушений
DK3525583T3 (da) 2016-10-12 2025-10-27 Bioverativ Usa Inc Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
KR20230144096A (ko) 2016-10-18 2023-10-13 씨젠 인크. 니코틴아미드 아데닌 디뉴클레오티드의 구제 경로 저해제의 표적화된 전달
US10239862B2 (en) 2017-03-15 2019-03-26 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
WO2018175994A1 (en) 2017-03-24 2018-09-27 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
CA3060405C (en) 2017-04-18 2020-06-16 3M Innovative Properties Company Air filter media with post-pleat-deposited sorbent particles
JP7425606B2 (ja) 2017-04-27 2024-01-31 シージェン インコーポレイテッド 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US20200188525A1 (en) * 2017-09-02 2020-06-18 Abbvie Inc. Anti-egfr antibody drug conjugates (adc) and uses thereof
WO2019046858A1 (en) * 2017-09-02 2019-03-07 Abbvie Inc. ANTI-EGFR-DRUG ANTIBODY (ADC) CONJUGATES AND USES THEREOF
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
EA202091360A1 (ru) * 2017-12-01 2020-08-24 Сиэтл Дженетикс, Инк. Гуманизированные анти-liv1 антитела для лечения рака молочной железы
AU2019225845B2 (en) 2018-02-20 2024-06-20 Seagen Inc. Hydrophobic Auristatin F compounds and conjugates thereof
WO2020056198A2 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
WO2020056194A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
US20200113912A1 (en) 2018-09-12 2020-04-16 Silverback Therapeutics, Inc. Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
JP2022500413A (ja) 2018-09-12 2022-01-04 シルバーバック セラピューティックス インコーポレイテッド Ｔｏｌｌ様受容体アゴニストの抗体コンジュゲート
US12304968B2 (en) 2018-11-07 2025-05-20 Crispr Therapeutics Ag T-cells expressing anti-LIV1 chimeric antigen receptor
WO2020247574A1 (en) 2019-06-05 2020-12-10 Seattle Genetics, Inc. Methods of purifying masked antibodies
US20220233709A1 (en) 2019-06-05 2022-07-28 Seagen Inc. Masked Antibody Formulations
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
GB201908208D0 (en) * 2019-06-10 2019-07-24 Univ College Cardiff Consultants Ltd An anti-mitotic agent
JP2022541591A (ja) * 2019-07-22 2022-09-26 シージェン インコーポレイテッド がんの処置のためのヒト化抗ｌｉｖ１抗体
EP4013456A1 (en) 2019-08-15 2022-06-22 Silverback Therapeutics, Inc. Formulations of benzazepine conjugates and uses thereof
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
US20210228676A1 (en) 2019-12-09 2021-07-29 Seagen Inc. Combination Therapy With LIV1-ADC and PD-1 Antagonist
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
JP2023543026A (ja) * 2020-09-28 2023-10-12 シージェン インコーポレイテッド がんの処置のためのヒト化抗ｌｉｖ１抗体
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
WO2022198231A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
EP4370211A1 (en) 2021-07-14 2024-05-22 Seagen Inc. Antibody masking domains
EP4405387A1 (en) 2021-09-24 2024-07-31 Seagen Inc. Improved antibody masking domains
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
AU2023266865A1 (en) 2022-05-12 2025-01-02 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Camptothecin derivative and ligand-drug conjugate
WO2024109944A1 (zh) * 2022-11-25 2024-05-30 江苏恒瑞医药股份有限公司 抗liv-1抗体、其药物偶联物及其医药用途
WO2024165056A1 (en) * 2023-02-07 2024-08-15 LaNova Medicines Limited Antibodies targeting liv-1 and uses thereof
AU2024235054A1 (en) * 2023-03-15 2025-10-02 BioRay Pharmaceutical Co., Ltd. Anti-liv-1 antibody and anti-liv-1 antibody-drug conjugate, and pharmaceutical use thereof
WO2025021118A1 (zh) * 2023-07-25 2025-01-30 海南先声再明医药股份有限公司 配体-药物偶联物及其偶联连接子
WO2025146128A1 (zh) * 2024-01-05 2025-07-10 海南先声再明医药股份有限公司 抗liv-1的抗体及其用途
WO2025146137A1 (zh) * 2024-01-05 2025-07-10 海南先声再明医药股份有限公司 抗liv-1抗体药物偶联物及其用途
CN120040587B (zh) * 2025-04-27 2025-08-08 上海宏成药业有限公司 抗liv-1抗体或其抗原结合片段及其用途

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
AU663727B2 (en) 1991-08-22 1995-10-19 Becton Dickinson & Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
CA2132500A1 (en) 1994-09-20 1996-03-21 David Lockwood Manning Methods for predicting the behaviour of breast tumours
DE69626849T2 (de) 1995-12-22 2003-12-24 Bristol-Myers Squibb Co., Princeton Verzweigte hydrazongruppen enthaltende kuppler
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
EP0939824B1 (en) 1996-10-31 2007-06-06 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
WO1998034118A1 (en) 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51
CA2308029A1 (en) 1997-10-31 1999-05-14 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO1999025877A1 (en) 1997-11-18 1999-05-27 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
JP2002507387A (ja) 1997-12-24 2002-03-12 コリクサ コーポレイション 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法
CA2347906A1 (en) 1998-08-04 2000-02-17 Diadexus, Inc. A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
EP1953229A3 (en) 1998-10-15 2008-12-24 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
ATE371231T1 (de) 1999-02-05 2007-09-15 Samsung Electronics Co Ltd Verfahren und vorrichtung zur wiederauffindung von texturbildern
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
US6762020B1 (en) 1999-03-15 2004-07-13 Protein Design Labs, Inc. Methods of diagnosing breast cancer
EP1263780A2 (en) 2000-01-25 2002-12-11 Genentech, Inc. Liv-1 related protein, polynulceotides encoding the same and use thereof for treatment of cancer
AU2001264099A1 (en) 2000-06-13 2001-12-24 University College Cardiff Consultants Ltd. Zinc transporters
US6964849B2 (en) 2001-01-11 2005-11-15 Curagen Corporation Proteins and nucleic acids encoding same
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
AU2002322280A1 (en) 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003000012A2 (en) 2001-06-21 2003-01-03 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
WO2003075855A2 (en) 2002-03-08 2003-09-18 Protein Design Labs, Inc. Antibodies against cancer antigen tmeff2 and uses thereof
JP4741838B2 (ja) 2002-07-31 2011-08-10 シアトル ジェネティクス，インコーポレーテッド 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用
MXPA05007940A (es) 2003-01-27 2007-06-14 Biogen Idec Inc Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1.
WO2004067564A2 (en) * 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
KR20050010267A (ko) 2003-07-18 2005-01-27 삼성전자주식회사 식각장치
CN104998273A (zh) 2003-11-06 2015-10-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
WO2005058961A2 (en) 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
CA2575663C (en) 2004-07-30 2013-04-23 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
US20060222653A1 (en) 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
KR20080080482A (ko) 2005-09-07 2008-09-04 메디뮨 엘엘씨 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체
CN101622273A (zh) 2006-04-13 2010-01-06 诺瓦提斯疫苗和诊断公司 治疗、诊断或检测与liv-1过量表达相关的癌症的方法
PT2099823E (pt) * 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
RU2009140134A (ru) * 2007-04-23 2011-05-27 Вайет (Us) Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений
EP2615115A3 (en) 2007-11-30 2014-01-08 Glaxo Group Limited Antigen-binding constructs
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
EP2304631A1 (en) 2008-06-16 2011-04-06 Sividon Diagnostics GmbH Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
US20110195995A1 (en) 2008-10-14 2011-08-11 Wittliff James L Methods of Optimizing Treatment of Estrogen-Receptor Positive Breast Cancers
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
US20110165566A1 (en) 2009-07-09 2011-07-07 Wittliff James L Methods of optimizing treatment of breast cancer
MX2012002766A (es) 2009-09-03 2012-04-02 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
CA3211246A1 (en) * 2010-12-06 2012-06-14 Seagen Inc. Humanized antibodies to liv-1 and use of same to treat cancer
WO2012125712A2 (en) 2011-03-14 2012-09-20 Respira Health, Llc Lung tumor classifier for current and former smokers
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
EA202091360A1 (ru) 2017-12-01 2020-08-24 Сиэтл Дженетикс, Инк. Гуманизированные анти-liv1 антитела для лечения рака молочной железы
US12304968B2 (en) 2018-11-07 2025-05-20 Crispr Therapeutics Ag T-cells expressing anti-LIV1 chimeric antigen receptor
GB201908208D0 (en) 2019-06-10 2019-07-24 Univ College Cardiff Consultants Ltd An anti-mitotic agent

Also Published As

Publication number Publication date
DK2648752T3 (en) 2017-03-27
AU2019202530A1 (en) 2019-05-02
CY1118874T1 (el) 2018-01-10
AU2011338480B2 (en) 2017-03-16
IL273607A (en) 2020-05-31
SI3461847T1 (sl) 2021-03-31
RU2608646C2 (ru) 2017-01-23
AU2011338480A1 (en) 2013-06-13
US20180079810A1 (en) 2018-03-22
PT3156420T (pt) 2019-05-27
MX2020010639A (es) 2020-10-28
PT2648752T (pt) 2017-03-28
IL226754B (en) 2018-10-31
HUE052806T2 (hu) 2021-05-28
EP2648752A4 (en) 2015-05-20
US20130259860A1 (en) 2013-10-03
CN103533957B (zh) 2016-06-22
JP6869218B2 (ja) 2021-05-12
JP6453924B2 (ja) 2019-01-16
US9228026B2 (en) 2016-01-05
IL299837A (en) 2023-03-01
CY1121546T1 (el) 2020-05-29
KR20200145867A (ko) 2020-12-30
EP3461847A8 (en) 2021-04-14
WO2012078688A3 (en) 2012-08-23
LT2648752T (lt) 2017-04-10
PL3156420T3 (pl) 2019-08-30
PL2648752T3 (pl) 2017-07-31
HRP20170567T1 (hr) 2017-06-16
MX2013006365A (es) 2013-08-15
WO2012078688A2 (en) 2012-06-14
SG190938A1 (en) 2013-07-31
CA3211246A1 (en) 2012-06-14
JP2019073515A (ja) 2019-05-16
US20240247059A1 (en) 2024-07-25
KR20190076068A (ko) 2019-07-01
IL273607B2 (en) 2023-06-01
NZ611468A (en) 2015-06-26
ES2842895T3 (es) 2021-07-15
SI2648752T1 (sl) 2017-06-30
JP7166384B2 (ja) 2022-11-07
JP2014506120A (ja) 2014-03-13
KR20220011811A (ko) 2022-01-28
ZA201303803B (en) 2014-07-30
US9783608B2 (en) 2017-10-10
EP3156420B1 (en) 2019-02-20
JP2021106599A (ja) 2021-07-29
EP2648752B1 (en) 2017-02-15
AU2017203851B2 (en) 2019-01-31
SG10201912646UA (en) 2020-02-27
JP2024178209A (ja) 2024-12-24
PT3461847T (pt) 2020-12-24
RS55843B1 (sr) 2017-08-31
AU2011338480A8 (en) 2017-03-23
MX379481B (es) 2025-03-11
RU2013130609A (ru) 2015-01-20
SG10201510041QA (en) 2016-01-28
SI3156420T1 (sl) 2019-05-31
HUE043355T2 (hu) 2019-08-28
AU2019202530B2 (en) 2021-04-01
ES2719548T3 (es) 2019-07-11
EP3461847A1 (en) 2019-04-03
AU2021204473A1 (en) 2021-07-29
AU2021204473B2 (en) 2024-07-18
CA2819038A1 (en) 2012-06-14
AU2011338480B8 (en) 2017-03-23
EP3156420A1 (en) 2017-04-19
IL261900A (en) 2018-10-31
DK3461847T3 (da) 2020-12-14
BR112013013781A2 (pt) 2016-09-13
KR20230057485A (ko) 2023-04-28
KR101993921B1 (ko) 2019-06-28
JP6105481B2 (ja) 2017-03-29
BR122021020513B1 (pt) 2022-10-25
AU2017203851A1 (en) 2017-06-22
PL3461847T3 (pl) 2021-07-05
US20160185858A1 (en) 2016-06-30
EP3461847B1 (en) 2020-09-23
CA2819038C (en) 2023-10-17
CN103533957A (zh) 2014-01-22
US20200165335A1 (en) 2020-05-28
USRE48959E1 (en) 2022-03-08
JP2023011709A (ja) 2023-01-24
CY1123883T1 (el) 2022-03-24
DK3156420T3 (en) 2019-04-29
EP3786185A1 (en) 2021-03-03
EP2648752A2 (en) 2013-10-16
KR20130135884A (ko) 2013-12-11
MX351027B (es) 2017-09-28
HUE031726T2 (en) 2017-07-28
JP2017149717A (ja) 2017-08-31
KR102198189B1 (ko) 2021-01-05

Similar Documents

Publication Publication Date Title
ES2620264T3 (es) Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
PE20181076A1 (es) Nuevos moduladores y metodos para su uso
AR132864A2 (es) UN ANTICUERPO QUE SE UNE ESPECÍFICAMENTE A a-SINUCLEÍNA HUMANA, UN ANTICUERPO HUMANIZADO, UNA FORMULACIÓN FARMACÉUTICA QUE COMPRENDE EL ANTICUERPO, Y LA UTILIZACIÓN DEL ANTICUERPO
AR122771A2 (es) Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped
CY1120471T1 (el) Αντισωματα κατα του cd70
AR082518A1 (es) Anticuerpos contra il-18r1 y usos de los mismos
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
ES2621874T3 (es) Anticuerpos para MUC16 y métodos de uso de los mismos
AR077595A1 (es) Tratamientos de combinacion
CY1117859T1 (el) Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
CR20120312A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
NZ609549A (en) Silent fc variants of anti-cd40 antibodies
AR079336A1 (es) Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
ES2572215T3 (es) Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
NZ703653A (en) Anti-fap antibodies and methods of use
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
PE20141151A1 (es) Proteinas de union al antigeno cd27l
CY1115700T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
PE20180042A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
NZ598791A (en) Anti-gcc antibody molecules and related compositions and methods
AR083747A1 (es) Anticuerpos anti-il-23